ACTUATE THERAPEUTICS INC
ACTUNASDAQ🏆 #4846 by market capEarnings Nov 13US Equity
$0.38▼ $0.01 (−2.58%)
Market closed · at closeTrack ACTU
Get earnings, price moves & breaking news on Telegram
24h▼ 2.6%
7d▼ 23.7%
14d▼ 24.4%
30d▼ 46.3%
ytd▼ 93.7%
1y▼ 94.1%
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.36 – $0.40
- 52-Week Range
- $0.41 – $7.90
- Volume (shares)
- 4,540
- Avg Volume (shares)
- —
- Shares Outstanding
- 24.0M
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.89
- Dividend Yield
- —
- Dilution (1yr)
- +19.1%
ACTUATE THERAPEUTICS INC
ACTUFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −10.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −12.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.2M▲ +19.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13M▲ +$4M YoY
StockOtter · stockotter.spaceAbout ACTUATE THERAPEUTICS INC
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.